M D Snape

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. doi request reprint The challenge of post-implementation surveillance for novel meningococcal vaccines
    Matthew D Snape
    Oxford Universities Hospitals NHS Trust, United Kingdom
    Vaccine 30:B67-72. 2012
  2. doi request reprint Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial
    Matthew D Snape
    Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom
    Pediatr Infect Dis J 29:e71-9. 2010
  3. ncbi request reprint Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine
    Matthew D Snape
    Department of Paediatrics, University of Oxford, Oxford, UK
    Pediatr Infect Dis J 28:92-7. 2009
  4. pmc Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
    M D Snape
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ
    BMJ 336:1487-91. 2008
  5. ncbi request reprint Meningococcal polysaccharide-protein conjugate vaccines
    Matthew D Snape
    Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK
    Lancet Infect Dis 5:21-30. 2005
  6. doi request reprint Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
    Matthew D Snape
    Oxford Vaccine Group, University of Oxford, England
    JAMA 299:173-84. 2008
  7. ncbi request reprint Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
    Matthew D Snape
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LJ, United Kingdom
    Clin Infect Dis 43:1387-94. 2006
  8. ncbi request reprint African tick bite fever
    Matthew D Snape
    Department of Paediatrics, University of Oxford, Oxford, UK
    Lancet Infect Dis 6:750. 2006
  9. ncbi request reprint Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine
    Matthew D Snape
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    Pediatr Infect Dis J 24:128-31. 2005
  10. pmc Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans
    Geraldine Blanchard-Rohner
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Oxford, United Kingdom
    Blood 114:4998-5002. 2009

Detail Information

Publications16

  1. doi request reprint The challenge of post-implementation surveillance for novel meningococcal vaccines
    Matthew D Snape
    Oxford Universities Hospitals NHS Trust, United Kingdom
    Vaccine 30:B67-72. 2012
    ..Although designed to prevent serogroup B meningococcal disease the vaccine antigens are not serogroup specific, creating the potential for multiple definitions of vaccine effectiveness and vaccine failure...
  2. doi request reprint Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial
    Matthew D Snape
    Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom
    Pediatr Infect Dis J 29:e71-9. 2010
    ....
  3. ncbi request reprint Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine
    Matthew D Snape
    Department of Paediatrics, University of Oxford, Oxford, UK
    Pediatr Infect Dis J 28:92-7. 2009
    ..We therefore assessed the use of glycoconjugate vaccines as an alternative method of demonstrating immunologic memory...
  4. pmc Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
    M D Snape
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ
    BMJ 336:1487-91. 2008
    ..To determine the persistence of bactericidal antibody titres following immunisation with serogroup C meningococcal glycoconjugate vaccine at age 6-15 years in order to examine changes in persistence of antibodies with age...
  5. ncbi request reprint Meningococcal polysaccharide-protein conjugate vaccines
    Matthew D Snape
    Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK
    Lancet Infect Dis 5:21-30. 2005
    ..Clinical trials are underway to assess new combination conjugate vaccines (containing A, C, Y, and W polysaccharides), and it is probable that these more broadly protective vaccines will become available in the near future...
  6. doi request reprint Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
    Matthew D Snape
    Oxford Vaccine Group, University of Oxford, England
    JAMA 299:173-84. 2008
    ..However, the currently licensed vaccine is poorly immunogenic in infancy, when the highest rates of disease are observed...
  7. ncbi request reprint Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
    Matthew D Snape
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LJ, United Kingdom
    Clin Infect Dis 43:1387-94. 2006
    ....
  8. ncbi request reprint African tick bite fever
    Matthew D Snape
    Department of Paediatrics, University of Oxford, Oxford, UK
    Lancet Infect Dis 6:750. 2006
  9. ncbi request reprint Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine
    Matthew D Snape
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    Pediatr Infect Dis J 24:128-31. 2005
    ..A serum bactericidal titer of <1/8 correlates with susceptibility to invasive meningococcal disease. We assessed this correlate of protection in a cohort of children approximately 2 years after a single dose of vaccine...
  10. pmc Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans
    Geraldine Blanchard-Rohner
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Oxford, United Kingdom
    Blood 114:4998-5002. 2009
    ....
  11. doi request reprint Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants
    Kirsten P Perrett
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Centre for Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK
    Pediatr Infect Dis J 28:186-93. 2009
    ..We evaluated the immunogenicity and reactogenicity of a novel quadrivalent nonadjuvanted meningococcal glycoconjugate vaccine (MenACWY-CRM) in healthy infants...
  12. pmc Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine
    Dominic F Kelly
    Oxford Vaccine Group, Department of Paediatrics, Oxford University, Oxford, UK
    Immunology 127:134-43. 2009
    ..This study provides data on B-cell kinetics following a primary schedule of immunization in young infants upon which to base further studies of the underlying cellular mechanism of humoral immunity...
  13. ncbi request reprint The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response
    Geraldine Blanchard Rohner
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK
    J Immunol 180:2165-73. 2008
    ..These findings suggest that these two parameters are good markers of B cell responses to priming and can be used as predictors of long term humoral immunity induced by glycoconjugate vaccines received in early infancy...
  14. doi request reprint A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children
    P De Whalley
    Department of Paediatrics, University of Oxford, Oxford, UK
    Health Technol Assess 15:v-vi, xi-xiii, 1-128. 2011
    ..Pandemic influenza A H1N1 infections occurred worldwide from 2009. Children were particularly vulnerable. Novel vaccines were used during the pandemic...
  15. pmc Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood
    A Khatami
    Oxford Vaccine Group, University of Oxford, CCVTM, Churchill Drive, Churchill Hospital, Oxford, OX3 7LJ, UK
    Clin Vaccine Immunol 18:2038-42. 2011
    ..Sustaining high levels of antibody through booster vaccination in this cohort is likely necessary to avoid a resurgence of disease in the decade ahead...
  16. pmc Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
    Claire S Waddington
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LJ
    BMJ 340:c2649. 2010
    ..To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom...